Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5153 Monotherapy and with Olaparib in Advanced Solid Tumors
NCT03205176Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2017
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of AZD5153 in solid tumor, lymphoma, High-Grade Serous Ovarian Carcinoma (HGSOC) and 3 more (2 arms), sponsored by AstraZeneca. Primary endpoint: Incidence of dose-limiting toxicity at 21 days. Started Jun 2017; status: completed.
02
Drugs
AZD5153
03
Conditions
solid tumorlymphomaHigh-Grade Serous Ovarian Carcinoma (HGSOC)triple negative breast cancer (TNBC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03205176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205176.